Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Guarnieri

Internal Medicine Webster, MA Medical Doctor

NPI 1679547830 CMS profile 30865

72 Cudworth Rd, Webster, MA 01570

Open in the dashboard

General payments

$28,247

1,498 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Guarnieri of Webster, MA is reported in the CMS Open Payments database as having received $28,247 across 1,498 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,543 203
2024 General $3,931 190
2023 General $5,056 266
2022 General $4,690 259
2021 General $4,341 242
2020 General $3,043 179
2019 General $2,645 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Guarnieri
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kenneth Guarnieri were reported at $4,543. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kenneth Guarnieri Internal Medicine median Middle half National median
2019 $2,645 $159 $48–$570 $163
2020 $3,043 $119 $33–$402 $114
2021 $4,341 $135 $37–$521 $132
2022 $4,690 $141 $42–$496 $149
2023 $5,056 $149 $45–$519 $160
2024 $3,931 $154 $47–$537 $164
2025 $4,543 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,861 239 payments
  2. AbbVie, Inc. $2,666 134 payments
  3. Pfizer Inc. $2,124 125 payments
  4. Lilly USA, LLC $2,066 107 payments
  5. Amgen Inc. $1,865 114 payments
  6. Novo Nordisk Inc $1,637 90 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $1,424 68 payments
  8. Novartis Pharmaceuticals Corporation $999 51 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $853 60 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $825 46 payments
  11. Other $8,928 464 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $28,197 1,492 payments
  2. Education $50 6 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $2,431 119 payments
  2. Repatha $1,459 94 payments
  3. MOUNJARO $1,052 42 payments
  4. Ozempic $1,020 59 payments
  5. NURTEC ODT $938 60 payments
  6. JARDIANCE Diabetes $923 60 payments
  7. JARDIANCE Diabetes $904 43 payments
  8. XIFAXAN $853 60 payments
  9. LINZESS $848 42 payments
  10. RYBELSUS $842 50 payments
  11. Other $24,048 1,285 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 160 drugs

Part D claims

13,406

Median for Internal Medicine: 777

Drug cost

$1,036,780

Median for Internal Medicine: $73,373

Branded share of claims

18.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 209 $178,378
Jardiance Empagliflozin Brand 131 $129,183
Januvia Sitagliptin Phosphate Brand 94 $99,276
Farxiga Dapagliflozin Propanediol Brand 107 $82,622
Zenpep Lipase/Protease/Amylase Brand 25 $56,615
Mounjaro Tirzepatide Brand 43 $48,260
Repatha Sureclick Evolocumab Brand 52 $36,897
Ozempic Semaglutide Brand 40 $34,772
Trulicity Dulaglutide Brand 25 $33,583
Xarelto Rivaroxaban Brand 28 $31,511

The 10 drugs with the highest cost, of 160 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$119,755

Medicare's payments for the services billed

Medicare patients

267

Average age 72

Services billed

1,983

128 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 37%
Diabetes 36%
COPD 24%
Osteoporosis 24%
Ischemic heart disease 22%
Atrial fibrillation 20%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$243 43 —
Repatha
$211 65 —
JARDIANCE
$209 131 —
LEQVIO
$186 — —
XIFAXAN
$184 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

1,498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record